Efficacy and safety of donepezil in patients with dementia with Lewy bodies: Preliminary findings from an open-label study

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 2, 2006, Pages 190-195

  Mori, Satoru ^a   Mori, Etsuro ^b   Iseki, Eizo ^c   Kosaka, Kenji ^d  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cholinesterase inhibitors; Dementia with Lewy bodies; Donepezil; Efficacy; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MALE; MENTAL DISEASE; MULTICENTER STUDY; PARKINSON DISEASE; STOMACH DISCOMFORT; TIME SERIES ANALYSIS;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; FEASIBILITY STUDIES; FEMALE; HUMANS; INDANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33644948649     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01485.x     Document Type: Article

References (25)

1. Kosaka K Yoshimura M Ikeda K Budka H Diffuse type of Lewy body disease: Progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: A new disease? ClinNeuropathol 1984 3 185 192
2. Perry RH Irving D Blessed G Fairbairn A Perry EK Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly JNeurosci 1990 95 119 139
3. Corey-Bloom J Thal LJ Galasko D et al. Diagnosis and evaluation of dementia Neurology 1995 45 211 218
4. McKeith IG Galasko D Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop Neurology 1996 47 1118 1124
5. Samuel W Alford M Hofstetter CR Hansen LJ Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density JNeuropatholExpNeurol 1997 56 499 508
6. Levy R Eagger S Griffiths M et al. Lewy bodies and response to tacrine in Alzheimer's disease Lancet 1994 343 176
7. McKeith I Del Ser T Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled international study Lancet 2000 356 2031 2036
8. Shea C MacKnight C Reckwood K Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients IntPsychogeriatr 1998 10 229 238
9. Edwards KR Hershey L Wray L et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 12-week interim analysis DementGeriatrCognDisord 2004 17 40 48
10. Folstein MF Folstein SE McHugh PR 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician JPsychiatrRes 1975 12 189 198
11. Hoehn MM Yahr MD Parkinsonism: Onset, progression, and mortality Neurology 1967 17 427 442
12. Finkel SI Costa e Silva J Cohen G Miller S Sartorius N Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment IntPsychogeriatr 1996 8 Suppl. 3 497 500
13. Cummings JL Mega M Gray K Rosenberg-Thompson S Carusi DA Gornbein J The Neuropsychiatric Inventory; Comprehensive assessment of psychopathology in dementia Neurology 1994 44 2308 2314
14. Hirono N Mori E Ikejiri Y et al. Japanese version of the neuropsychiatric inventory: A scoreing system for neuropsychiatric disturbances in dementia patients Noshinkei 1997 49 266 271 (in Japanese).
15. Homma A Fukuzawa K Tsukada Y Ishii T Hasegawa K Mohs RC Development of a Japanese version of Alzheimer's disease Assessment Scale (ADAS) Jpn JGeriatrPsychiatry 1992 3 647 655 (in Japanese).
16. Mohs RC Rosen WG Davis KL The Alzheimer's disease assessment scale: An instrument for assessing treatment efficacy PsychopharmacolBull 1983 19 448 450
17. Fahn S Elton R Unified Parkinson's disease rating scale In Fahn S Marsden CD Calne D (eds) Recent Developments in Parkinson's Disease Macmillan New York 1987 153 163
18. Ballard CG Aarsland D McKeith I et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism Neurology 2002 59 1714 1720
19. Walker MP Ayre GA Cummings JL et al. The clinician assessment of fluctuation and the one day fluctuation assessment scale BrJPsychiatry 2000 177 252 256
20. Kaufer DI Catt KE Lopez OL DeKosky ST Dementia with Lewy bodies: Response of delirium-like features to donepezil Neurology 1998 51 1512
21. Perry EK Perry RH Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness Brain Cogn 1995 28 240 258
22. Aarsland D Laake K Larsen JP Janvin C Donepezil for cognitive impairment in Parkinson's disease: A randomized controlled study JNeurolNeurosurgPsychiatry 2002 72 708 712
23. Leroi I Brandt J Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease IntJGeriatrPsychiatry 2004 19 1 8
24. Hutchinson M Fazzini E Cholinesterase inhibition in Parkinson's disease JNeurolNeurosurgPsychiatry 1996 61 324 325
25. Piggott MA Owens J O'Brien J et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease JChemNeuroanat 2003 25 161 173